BB Biotech
From Wikipedia, the free encyclopedia
 |
|
| Type | Aktiengesellschaft |
|---|---|
| Traded as | SIX: BION, FWB: BBZA |
| Industry | Investments |
| Founded | Schaffhausen, Switzerland (9 November 1993) |
| Headquarters | Küsnacht, Switzerland |
| Key people | Thomas D. Szucs (Chairman) |
| Products | Investment in biotechnology companies |
| Operating income | CHF 1.6 million (2010)[1] |
| Profit |  (CHF 146.3 million) (2010)[1] |
| Total assets | CHF 1.377 billion (2010)[1] |
| Total equity | CHF 1.235 billion (2010)[1] |
| Website | www.bbbiotech.ch |
BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and since 2000 on the Italian Borsa Italiana.[2]
At the end of 2010 the six largest holdings in the BB Biotech portfolio were (in order of value): a 3.8% stake in Actelion; 0.9% of Celgene; 0.7% of Gilead Sciences; 2.5% of Vertex Pharmaceuticals; 0.2% of Novo Nordisk and 3.2% of Incyte.[1]
[edit] References
- ^ a b c d e "Annual Report 2010" (PDF). BB Biotech. http://www.bbbiotech.ch/fileadmin/user_upload/files/bbbiotech/en/pdf/Annual_Reports/2010/BION_Annual_Report_2010_EN.pdf. Retrieved 13 March 2011.
- ^ "BB Biotech - Facts & Figures". BB Biotech. http://www.bbbiotech.ch/en/bb-biotech/investor-relations/facts-figures/. Retrieved 2009-04-28.
[edit] External links
 |
This Swiss corporation or company article is a stub. You can help Wikipedia by expanding it. |
